Minova Life Science

Minova life sciences - Pharmaceutical company

Vildafast-M 50 Tablets, Vildagliptin  IP 50 mg +, Diabetic Tablet

COMPOSITION – Vildagliptin  IP 50 mg + Metformin Hydrochloride IP 500 mg


▸ Vildafast-M  is Inhibits dipeptidyl peptidase-4 and prevents degradation of glucagon like peptide-1 in patients with type 2 diabetes mellitus

No accumulation of drug is seen following the administration of multiple doses because of short elimination life

▸Vildafast-M Does not possess adverse gastrointestinal events compliance and adherence to patients improves


▸ First line therapy for patients with Type 2 Diabetes Mellitus

▸ Combination therapy reduces the pill burden and improves patient compliance

Explore other products

Scroll to Top